What is the Orange Book, and where is it in the FDA database?
The FDA’s Orange Book is the “Approved Drug Products with Therapeutic Equivalence Evaluations.” It’s published by the FDA and lists drug products that have been approved under the FDA’s drug application system. The listing includes details such as the active ingredient, applicant/holder, dosage form/route, and approved patent/exclusivity information that can affect generic entry.
You can access the FDA Orange Book here: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
How do I search the Orange Book (ingredient, product name, or labeler)?
The Orange Book search lets you look up approved products by common fields, such as:
- Active ingredient (generic name)
- Product name/brand
- Applicant/labeler
- Application number (when you know it)
Once you select a product, the Orange Book page typically shows the product’s listing and links to associated patent and exclusivity information.
What’s the difference between “patents” and “exclusivity” in the Orange Book?
Orange Book entries often include two related but distinct concepts:
- Patents listed for a product (commonly shown as “Orange Book patents”)
- Non-patent exclusivities (FDA-granted exclusivity periods that can delay generic approval even if patents expire or are not the driving factor)
Both are shown to help explain timelines for potential generic competition.
How do Orange Book patents connect to ANDAs and FDA approvals?
Generic drug applicants (ANDA holders) use Orange Book information when preparing submissions. The Orange Book’s patent/exclusivity listings are used in the context of FDA’s generic drug regulatory pathway and “patent certification” frameworks, which can trigger patent litigation and affect approval timing.
Can I use DrugPatentWatch.com with the Orange Book?
If you’re looking for patent and exclusivity context beyond what the FDA entry shows, DrugPatentWatch.com compiles and tracks patent/exclusivity information for marketed drugs and can be used as a secondary source alongside the FDA Orange Book. https://www.drugpatentwatch.com/